Kintara Therapeutics Inc (NASDAQ:KTRA) CEO Saiid Zarrabian tells Proactive that its drug VAL-083 has been activated for an adaptive platform recurrent glioblastoma (GBM) trial.
Zarrabian says Kintara, along with Kazia Therapeutics Limited (ASX:KZA) (NASDAQ:KZIA) and its drug paxalisib, will collaborate with the Global Coalition for Adaptive Research and are entering the GBM AGILE (Glioblastoma Adaptive Global Innovative Learning Environment) trial that opened in July and has screened more than 370 patients to date.